

# **Wholesale Acquisition Cost (WAC) Disclosure for Connecticut Prescribers**



## WAC Information

In accordance with Connecticut Public Act No. 23-171, the WAC of ZURZUVAE® (zuranolone) 20, 25, and 30 mg capsules, CIV, as of January 1, 2026 is provided below.

Product/NDC# <sup>1</sup>	WAC per Package <sup>a,b</sup>
ZURZUVAE 20-mg Bottle/14 Count NDC 64406-0029-01	\$8,556.98
ZURZUVAE 25-mg Blister Pack/28 Count NDC 64406-0030-02	\$17,113.97
ZURZUVAE 30-mg Bottle/14 Count NDC 64406-0031-01	\$17,113.97

<sup>a</sup>The WAC is the manufacturer's undiscounted list price for a pharmaceutical product when it is sold to wholesalers, distributors, or other direct purchasers. The WAC does not represent an actual transaction price and does not include discounts, rebates, or other reductions in price.

<sup>b</sup>All costs are based on package size and assume 100% compliance and 100% efficient use of drug.

Out-of-pocket costs for an insured patient are likely lower than WAC depending on their insurance benefits.<sup>2</sup>

**References:** **1.** ZURZUVAE Prescribing Information. Cambridge, MA: Sage Therapeutics, Inc. and Biogen Inc. **2.** Novack GD. What determines how much your patient pays for their medication in the United States? *Am J Ophthalmol.* 2016;167:48-51.

Please see full [Prescribing Information](#), including **Boxed Warning**.

ZURZUVAE is a trademark of Sage Therapeutics licensed to Supernus Pharmaceuticals, Inc. BIOGEN and the BIOGEN logo are registered trademarks of Biogen Inc. SUPERNUS PHARMACEUTICALS and the SUPERNUS PHARMACEUTICALS logo are registered trademarks of Supernus Pharmaceuticals, Inc. All other trademarks referenced herein are the property of their respective owners.

© 2026 Supernus Pharmaceuticals, Inc. All rights reserved.

© 2026 Biogen. All rights reserved. ZUR-US-0177v4 04/26

